Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status

Targeted molecular therapy is an effective anticancer strategy. Anti‐EGFR monoclonal antibodies such as cetuximab (CTX) have been approved for the treatment of various malignancies, including colorectal cancer (CRC) with wild‐type KRAS. However, their efficacy in patients with KRAS mutations has not...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Junko, Futamura, Manabu, Kanematsu, Masako, Gaowa, Siqin, Mori, Ryutaro, Tanahashi, Toshiyuki, Matsuhashi, Nobuhisa, Yoshida, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057332/
https://www.ncbi.nlm.nih.gov/pubmed/26437179
http://dx.doi.org/10.1002/ijc.29881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057332/
https://www.ncbi.nlm.nih.gov/pubmed/26437179
http://dx.doi.org/10.1002/ijc.29881

Ejemplares similares